INBXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibrx Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$89.79−0.04 (-0.04%)
Close on Oct 19, 2026
- Market cap
- $1.41B
- P/E (TTM)
- –
- Dividend yield
- –
Inhibrx Biosciences, Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|
| License fee revenue | $1.30M | $200.00K | $1.80M | $2.18M | $7.13M | $12.81M | $9.09M | 100.0% | +550.0% |
| License fee revenue | $1.30M | $200.00K | $1.80M | $2.18M | $7.13M | $10.81M | $8.09M | 100.0% | +550.0% |
| Grant revenue | – | – | $0 | $14.00K | $106.00K | $80.00K | $4.12M | – | – |
| License fee revenue, affiliates | – | – | – | – | $0 | $2.00M | $1.00M | – | – |
By region
From the segment and revenue-disaggregation notes of Inhibrx Biosciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.